| CARLAT PUBLISHING

The post-test for this issue is available for one year after the publication date to subscribers only. By successfully completing the test you will be awarded a certificate for 1 CME credit. Read More

This 2019 randomized, double-blind, placebo- controlled trial study casts doubt on using gabapentin enacarbil extended-release (GE-XR) (Horizant), an extended-release version of gabapentin, for treatment in patients with alcohol use disorder Read More

This 2019 retrospective study examines the potential benefits of using buprenorphine/naloxone to treat co-occurring PTSD and opioid use disorder. Read More

Opioid Use Disorder: Is There an App for That?

This News of Note discusses the first FDA-approved mobile app for SUDs, called reSET-O. Classified as a mobile medical app (MMAs), reSET-O can be used as an adjunct to outpatient opioid use disorder treatment. Unlike most apps, reSET-O requires a prescription to unlock and use. Read More

Treating Addiction in Patients Transitioning to/from Incarceration

Addiction treatment during incarceration is limited, and release from incarceration presents its own set of challenges. In this QA interview, Dr. Karen Cropsey discusses effective treatment options for patients with substance use disorders transitioning to or from incarceration. Read More

Primer: Confidentiality in Addiction Treatment

Addiction is stigmatized, resulting in historically strict confidentiality rules. But how do we interpret HIPAA and other regulations in 2019 addiction practice? Do we need a ROI every time we communicate with other clinicians/institutions, which seems cumbersome and counterproductive? In this article we cover what you need to know about confidentiality in addiction treatment. Read More

Medication Fact Book for Psychiatric Practice, Seventh Edition (2024)
The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
READ MORE

General Psychiatry
Using SAMe In Clinical Practice with Garrett Rossi, MD
Read More

Addiction Treatment
Supervised Drug Consumption Sites
Once controversial, research clearly shows the benefit of these sites, and they have started opening in the United States.
Listen now